Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug Guides,Pharmacology (nursing)
Reference33 articles.
1. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of Phase I and II clinical trials of new anticancer agents. J Natl Cancer Instit. 1993;85:1637–1643.
2. Storer B, DeMets D. Current Phase I/II designs: are they adequate? J Clin Research and Drug Dev. 1987;1:121–130.
3. Mick R, Lane N, Faugherty C, Ratain MJ. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in Phase I cancer trials. J Natl Cancer Instit. 1994;86:1685–1693.
4. Durham SD, Flournoy N, Rosenberger WF. A random walk rule for Phase I clinical trials. Biometrics. 1997;53:745–760.
5. Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE. Clinical drug development: an analysis of Phase II trials, 1970–1985. Cancer Treat Rep. 1987;71:71–80.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献